A bioinformatics-based strategy identifies c-Myc and Cdc25A as candidates for the Apmt mammary tumor latency modifiers

Genome Research

Volumn 12, Issue 6, 2002, Pages 969-975

  Cozma, Diana ^a   Lukes, Luanne ^a   Rouse, Jessica ^a   Qiu, Ting Hu ^a   Liu, Edison T ^a,b   Hunter, Kent W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; TRANSCRIPTION FACTOR; VIRUS MIDDLE T ANTIGEN;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; BREAST TUMOR; CARCINOGENESIS; CELL CYCLE; CONGENIC STRAIN; CONTROLLED STUDY; GENE CONSTRUCT; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENE LOCUS; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC CODE; GENETIC EPISTASIS; GENETIC POLYMORPHISM; GROWTH ACCELERATION; LATENT PERIOD; MOLECULAR MIMICRY; MOLECULAR MODEL; MOUSE; NONHUMAN; ONCOGENE C MYC; ONSET AGE; PHENOTYPE; POLYOMA VIRUS; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE TRAIT LOCUS MAPPING; SEQUENCE ANALYSIS; TRANSGENE;

3T3 CELLS; ANIMALS; CDC25 PHOSPHATASE; COMPUTATIONAL BIOLOGY; EPISTASIS, GENETIC; GENES, MYC; GENETIC MARKERS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-MYC; QUANTITATIVE TRAIT, HERITABLE;

ANIMALIA; POLYOMAVIRUS;

EID: 0036079155     PISSN: 10889051     EISSN: None     Source Type: Journal    
DOI: 10.1101/gr.210502     Document Type: Article

References (33)

1. Myc and the cell cycle
2. Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors
3. QTL analysis andgenome-wide mutagenesis in mice: Complementary genetic approaches to the dissection of complex traits
4. Role of the Cdc25A phosphatase in human breast cancer
5. Amplification of c-myc gene and overexpression of c-Myc protein in breast cancer and adjacent non-neoplastic tissue
6. Cis-acting determinants of c-myc mRNA stability
7. Cooperation of oncogenes in the multistep transformation of established fibroblasts in culture
8. Streptococcal wall component OK432 restores sensitivity of non-obese diabetic (NOD) thymocytes to apoptotic signals
9. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13
10. Analysis of gene expression in single live neurons
11. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis
12. The genetics of breast and ovarian cancer
13. Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families
14. CDC25 phosphatases as potential human oncogenes
15. Cdc25 cell-cycle phosphatase as a target of c-myc
16. A large kindred with 17q-linked breast and ovarian cancer: Genetic, phenotypic, and genealogical analysis
17. Consed: A graphical tool for sequence finishing
18. Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease
19. Poly(dA:dT), a ubiquitous promoter element that stimulates transcription via its intrinsic DNA structure
20. Regulation of the Cdc25A gene by the human papillomavirus Type 16 E7 oncogene
21. A rare CYP19 (aromatase) variant may increase the risk of breast cancer
22. An association between the risk of cancer and mutations in the HRAS1 minisatellite locus
23. BRCA1 mutations in a population-based sample of young women with breast cancer
24. An epistatic interaction controls the latency of a transgene-induced mammary tumor
25. Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression
26. The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia
27. Risk modifiers in carriers of BRCA1 mutations
28. Human papillomavirus type 16 E7 maintains elevated levels of the cdc25A tyrosine phosphatase during deregulation of cell cycle arrest
29. Structure and promoter activity of the mouse CDC25A gene
30. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus
31. Poly(dA.dT) sequences exist as rigid DNA structures in nucleosome-free yeast promoters in vivo
32. Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc
33. Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1